Viking Therapeutics
VKTX
Performance
About Viking Therapeutics
Viking Therapeutics is a biotechnology company focused on developing novel therapeutics for metabolic and endocrine disorders. Its pipeline includes targeted therapies for obesity, nonalcoholic fatty liver disease (NASH), rare diseases like X-ALD, and other conditions affecting metabolism and energy homeostasis, with multiple programs such as VK2735, VK2809, VK0214, VK5211, VK0612, VK1430, and EPOR agonist programs. The company aims to address unmet medical needs in metabolic diseases and related metabolic/endocrine disorders, with development efforts likely centered in the United States.
Recent News
FDA Approves Eli Lilly’s Foundayo, Pitting First Oral Obesity Pill Against Novo Nordisk’s Wegovy
Viking Therapeutics Targets 170% Upside as Dual-Agonist Obesity Drug Shows 14.7% Weight Loss
Ceasefire Extension, Best Buy's New CEO, Amazon's GLP-1 Push and More in Morning Squawk
Viking Gets Commercial Chief While Other Obesity Biotechs Sell; Novo's Uli Stilz Steps Down
Nine Biotech Companies that Could Revolutionize Obesity Treatments
Some Implied Moves for Earnings Next Week(Apr. 27th – May 1st) – 726 Companies Reporting
Fool.com Analysts Flag Abivax and Viking Therapeutics as Potential Double‑digit Gainers by 2030
Viking Therapeutics Gains Strong‑Buy Consensus as Obesity Market Eyes $100B by 2030
Amazon Launches GLP‑1 Weight‑Loss Program, Targeting $100 B Market
Beyond Rezdiffra: The 4 Most Promising MASH Pipelines in Play
Viking Therapeutics Emerges as Prime Obesity‑Drug Acquisition Target
Deep Dive: The Oral Obesity Wars
Recent Deals
No recent deals for this company.